Glycotest Diagnostics is a brand dedicated to developing unique and non-invasive blood tests for liver cancers and fibrosis-cirrhosis. With the potential to revolutionize care and treatment for individuals at risk due to chronic liver disease, Glycotest aims to improve patient outcomes in the face of this growing health concern. Using cutting-edge technology, Glycotest's blood tests measure two types of disease signals to provide information on the likelihood of serious liver disease.

By analyzing the levels of abnormally appearing fucose on certain serum glycoproteins and monitoring the abnormal fucosylation patterns of glycoproteins, these tests can detect diseases like hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and fibrosis-cirrhosis. Key features of Glycotest's blood tests include their focus on early-stage disease detection, potentially outperforming currently available biomarkers. With liver cancer claiming over 700,000 lives annually and becoming the fastest-growing cause of cancer death in the US, Glycotest's mission to address this global threat is more important than ever.

Stay updated with Glycotest's latest news, including their recent patent grants and expansions, as they continue to pioneer advancements in early diagnosis and surveillance for liver cancer. To learn more about Glycotest and their innovative blood tests, visit their website or get in touch through their contact information provided